LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
Analyst Thomas Shrader of BTIG maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), reducing the price target to $12.00. Thomas Shrader gave his rating based on several factors, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback